The use of baseline clinical measures to predict those at risk for progression of benign prostatic hyperplasia.

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Although histologic changes of benign prostatic hyperplasia (BPH) begin in men when they are in their thirties, symptomatic BPH characterized by lower urinary tract symptoms (LUTS) typically do not develop for several decades. Progression of BPH may lead to significant voiding symptoms, acute urinary retention, and the need for prostate surgery. However, developing LUTS is not inevitable for men with histologic evidence of BPH. The ability to predict those men who are at risk for BPH progression is increasingly important because of recent evidence provided by the Medical Therapy of Prostate Symptoms study. This landmark study demonstrated that 5alpha-reductase inhibitors, alone or in combination with selective alpha-blockers, can delay or prevent the progression of BPH. In addition, the most important and consistent predictive factors for BPH progression are baseline prostate-specific antigen and prostate volume. Integration of these clinical parameters into clinical practice is influencing the decision regarding which men should observe or initiate treatment. This article highlights recent studies regarding the use of baseline clinical parameters on predicting BPH progression.

Original languageEnglish (US)
Pages (from-to)267-273
Number of pages7
JournalCurrent Urology Reports
Volume5
Issue number4
DOIs
StatePublished - Jan 1 2004
Externally publishedYes

Fingerprint

Prostatic Hyperplasia
Prostate
Lower Urinary Tract Symptoms
Urinary Retention
Prostate-Specific Antigen
Oxidoreductases
Therapeutics

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

The use of baseline clinical measures to predict those at risk for progression of benign prostatic hyperplasia. / Kim, Edward.

In: Current Urology Reports, Vol. 5, No. 4, 01.01.2004, p. 267-273.

Research output: Contribution to journalReview article

@article{4bbee29b4d5a4d709a8086dbaa82f377,
title = "The use of baseline clinical measures to predict those at risk for progression of benign prostatic hyperplasia.",
abstract = "Although histologic changes of benign prostatic hyperplasia (BPH) begin in men when they are in their thirties, symptomatic BPH characterized by lower urinary tract symptoms (LUTS) typically do not develop for several decades. Progression of BPH may lead to significant voiding symptoms, acute urinary retention, and the need for prostate surgery. However, developing LUTS is not inevitable for men with histologic evidence of BPH. The ability to predict those men who are at risk for BPH progression is increasingly important because of recent evidence provided by the Medical Therapy of Prostate Symptoms study. This landmark study demonstrated that 5alpha-reductase inhibitors, alone or in combination with selective alpha-blockers, can delay or prevent the progression of BPH. In addition, the most important and consistent predictive factors for BPH progression are baseline prostate-specific antigen and prostate volume. Integration of these clinical parameters into clinical practice is influencing the decision regarding which men should observe or initiate treatment. This article highlights recent studies regarding the use of baseline clinical parameters on predicting BPH progression.",
author = "Edward Kim",
year = "2004",
month = "1",
day = "1",
doi = "10.1007/s11934-004-0049-z",
language = "English (US)",
volume = "5",
pages = "267--273",
journal = "Current Urology Reports",
issn = "1527-2737",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - The use of baseline clinical measures to predict those at risk for progression of benign prostatic hyperplasia.

AU - Kim, Edward

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Although histologic changes of benign prostatic hyperplasia (BPH) begin in men when they are in their thirties, symptomatic BPH characterized by lower urinary tract symptoms (LUTS) typically do not develop for several decades. Progression of BPH may lead to significant voiding symptoms, acute urinary retention, and the need for prostate surgery. However, developing LUTS is not inevitable for men with histologic evidence of BPH. The ability to predict those men who are at risk for BPH progression is increasingly important because of recent evidence provided by the Medical Therapy of Prostate Symptoms study. This landmark study demonstrated that 5alpha-reductase inhibitors, alone or in combination with selective alpha-blockers, can delay or prevent the progression of BPH. In addition, the most important and consistent predictive factors for BPH progression are baseline prostate-specific antigen and prostate volume. Integration of these clinical parameters into clinical practice is influencing the decision regarding which men should observe or initiate treatment. This article highlights recent studies regarding the use of baseline clinical parameters on predicting BPH progression.

AB - Although histologic changes of benign prostatic hyperplasia (BPH) begin in men when they are in their thirties, symptomatic BPH characterized by lower urinary tract symptoms (LUTS) typically do not develop for several decades. Progression of BPH may lead to significant voiding symptoms, acute urinary retention, and the need for prostate surgery. However, developing LUTS is not inevitable for men with histologic evidence of BPH. The ability to predict those men who are at risk for BPH progression is increasingly important because of recent evidence provided by the Medical Therapy of Prostate Symptoms study. This landmark study demonstrated that 5alpha-reductase inhibitors, alone or in combination with selective alpha-blockers, can delay or prevent the progression of BPH. In addition, the most important and consistent predictive factors for BPH progression are baseline prostate-specific antigen and prostate volume. Integration of these clinical parameters into clinical practice is influencing the decision regarding which men should observe or initiate treatment. This article highlights recent studies regarding the use of baseline clinical parameters on predicting BPH progression.

UR - http://www.scopus.com/inward/record.url?scp=16544394058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16544394058&partnerID=8YFLogxK

U2 - 10.1007/s11934-004-0049-z

DO - 10.1007/s11934-004-0049-z

M3 - Review article

VL - 5

SP - 267

EP - 273

JO - Current Urology Reports

JF - Current Urology Reports

SN - 1527-2737

IS - 4

ER -